CEO of Cybin Inc.
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
New findings from an animal study show that psychedelics open a ‘critical period’ of social reward learning in the brain, but that different psychedelics do so...
Eleven major neuroscientific research projects related to “The Science of Perception Box” are being funded by the Tiny Blue Dot Foundation, each project receiving three consecutive...
Psilera, a biopharmaceutical company developing next-generation mental health treatments for take-home use, announces the selection of their lead clinical candidate, PSIL-006.
A study has provided new insights into how psychedelics promote plasticity in the brain – suggesting that the antidepressant effects and the hallucinatory effects may have...
A new analysis led by NYU Grossman School of Medicine and the National Drug Early Warning System (NDEWS) at the University of Florida found a 349%...
Algernon NeuroScience (AGN Neuro) has announced that its Phase 1 DMT trial is complete.
New research suggests that ketamine nasal spray may prove a safe and effective treatment for refractory chronic migraine.
A study has been launched that is investigating COMP360 psilocybin therapy – an investigational new therapy – for treatment-resistant depression (TRD).